Kasey L. Couts

Dr. Kasey L. Couts

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
FNFelicity Newell
Felicity Newell
PJPeter A. Johansson
Peter A. Johansson
JWJames Wilmott
James Wilmott
Katia NonesKatia Nones
Katia Nones
VLVanessa Lakis
Vanessa Lakis
Nicholas K. HaywardNicholas K. Hayward
Nicholas K. Hayward
Melanoma is a cancer of melanocytes, with multiple subtypes based on body site location. Cutaneous melanoma is associated with skin exposed to ultraviolet radiation; uveal melanoma occurs in the eyes; mucosal melanoma occurs in internal mucous membranes; and acral melanoma occurs on the palms, soles, and nail beds. Here, we present the largest whole-genome sequencing study of melanoma to date, with 570 tumors profiled, as well as methylation and RNA sequencing for subsets of tumors. Uveal melanoma is genomically distinct from other melanoma subtypes, harboring the lowest tumor mutation burden and with significantly mutated genes in the G-protein signaling pathway. Most cutaneous, acral, and mucosal melanomas share alterations in components of the MAPK, PI3K, p53, p16, and telomere pathways. However, the mechanism by which these pathways are activated or inactivated varies between melanoma subtypes. Additionally, we identify potential novel germline predisposition genes for some of the less common melanoma subtypes. Significance: This is the largest whole-genome analysis of melanoma to date, comprehensively comparing the genomics of the four major melanoma subtypes. This study highlights both similarities and differences between the subtypes, providing insights into the etiology and biology of melanoma. This article is highlighted in the In This Issue feature, p. 2711

15 November 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RTRichard Tobin
Richard Tobin
DCDasha T. Cogswell
Dasha T. Cogswell
VCVictoria M. Cates
Victoria M. Cates
DDDana M. Davis
Dana M. Davis
JBJessica Borgers
Jessica Borgers
MMMartin McCarter
Martin McCarter
Purpose: A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of the combination of all-trans retinoic acid (ATRA) with pembrolizumab in patients with stage IV melanoma. Patients and Methods: Anti–PD-1 naïve patients with stage IV melanoma were treated with pembrolizumab plus supplemental ATRA for three days surrounding each of the first four pembrolizumab infusions. The primary objective was to establish the MTD and recommended phase II dose (RP2D) of the combination. The secondary objectives were to describe the safety and toxicity of the combined treatment and to assess antitumor activity in terms of (i) the reduction in circulating myeloid-derived suppressor cell (MDSC) frequency and (ii) progression-free survival (PFS). Results: Twenty-four patients were enrolled, 46% diagnosed with M1a and 29% with M1c stage disease at enrollment. All patients had an ECOG status ≤1, and 75% had received no prior therapies. The combination was well tolerated, with the most common ATRA-related adverse events being headache, fatigue, and nausea. The RP2D was established at 150 mg/m2 ATRA + 200 mg Q3W pembrolizumab. Median PFS was 20.3 months, and the overall response rate was 71%, with 50% of patients experiencing a complete response, and the 1-year overall survival was 80%. The combination effectively lowered the frequency of circulating MDSCs. Conclusions: With a favorable tolerability and high response rate, this combination is a promising frontline treatment strategy for advanced melanoma. Targeting MDSCs remains an attractive mechanism to enhance the efficacy of immunotherapies, and this combination merits further investigation. See related commentary by Olson and Luke, p. 1167

21 July 2020 in Melanoma Research
Verified
Journal Article
Closed access
BHBlair N. Holman
Blair N. Holman
RGRobert J. Van Gulick
Robert J. Van Gulick
CACarol M. Amato
Carol M. Amato
MMMorgan L. MacBeth
Morgan L. MacBeth
KDKurtis D. Davies
Kurtis D. Davies
KCKasey L. Couts
Kasey L. Couts
Subungual melanomas (SUM) arise beneath the nails of the hands and feet, and account for 0.7–3.5% of all malignant melanomas. Most studies include SUM in the category of acral melanoma, but understanding the specific features of SUM is critical for improving patient care. In this study, we performed a site-specific comparison of the clinical and molecular features between 54 cases of SUM and 78 cases of nonsubungual acral melanoma. Compared to patients with acral melanoma, patients with SUM were younger at diagnosis, had a higher prevalence of primary melanomas on the hand, and had more frequent reports of previous trauma at the tumor site. SUM was deeper than acral melanoma at diagnosis, which correlated with an increased frequency of metastases. Analysis of common melanoma driver genes revealed KIT and KRAS mutations were predominantly found in SUM, whereas BRAF and NRAS mutations occurred almost exclusively in acral melanoma. We also discovered molecular differences in the cell cycle pathway, where CDK4/CCND1 amplifications were more frequent in SUM and CDKN2A/B loss occurred mostly in acral melanoma, and in the PI3K/mTOR pathway, where RICTOR amplification and TSC1 K587R mutations were exclusively in SUM and PTEN loss and AKT1 mutations were exclusively in acral melanoma. Comparison of hand versus foot tumors revealed more frequent ulceration of SUM foot tumors, which correlated with more distal metastases and poorer overall survival. In summary, we find SUM are both clinically and molecularly distinct from acral melanoma, and our data suggest KIT, CDK4/6, and mTOR inhibitors may be particularly relevant and effective treatments for patients with SUM.

1 February 2020 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
JBJessica Borgers
Jessica Borgers
RTRichard Tobin
Richard Tobin
VVVictoria M. Vorwald
Victoria M. Vorwald
JSJoshua M. Smith
Joshua M. Smith
DDDana M. Davis
Dana M. Davis
MMMartin McCarter
Martin McCarter
Although the consequences of splenectomy are well understood in mice, much less is known about the immunologic changes that occur following splenectomy in humans. We sought to characterize the circulating immune cell populations of patients before and after elective splenectomy to determine if these changes are related to postsplenectomy survival outcomes. Retrospective clinical information was collected from 95 patients undergoing elective splenectomy compared with 91 patients undergoing pancreaticoduodenectomy (Whipple procedure). We further analyzed peripheral blood from five patients in the splenectomy group, collected before and after surgery, using single-cell cytometry by time-of-flight mass spectrometry. We compared pre- and postsplenectomy data to characterize both the major and minor immune cell populations in significantly greater detail. Compared with patients undergoing a Whipple procedure, splenectomized patients had significant and long-lasting elevated counts of lymphocytes, monocytes, and basophils. Cytometry by time-of-flight mass spectroscopy analysis demonstrated that the elevated lymphocytes primarily consisted of naive CD4+ T cells and a population of activated CD25+CD56+CD4+ T cells, whereas the elevated monocyte counts were mainly mature, activated monocytes. We also observed a significant increase in the expression of the chemokine receptors CCR6 and CCR4 on several cellular populations. Taken together, these data indicate that significant immunological changes take place following splenectomy. Whereas other groups have compared splenectomized patients to healthy controls, this study compared patients undergoing elective splenectomy to those undergoing a similar major abdominal surgery. Overall, we found that splenectomy results in significant long-lasting changes in circulating immune cell populations and function.

20 December 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
NMNabanita Mukherjee
Nabanita Mukherjee
CDChiara R. Dart
Chiara R. Dart
CACarol Amato
Carol Amato
AHAdam Honig-Frand
Adam Honig-Frand
JLJames R. Lambert
James R. Lambert
YSYiqun Shellman
Yiqun Shellman

12 July 2024 in International Journal of Cancer
Verified
Journal Article
Closed access
JTJacqueline A. Turner
Jacqueline A. Turner
RGRobert J. Van Gulick
Robert J. Van Gulick
WRWilliam A. Robinson
William A. Robinson
TMTariq Mughal
Tariq Mughal
RTRichard P. Tobin
Richard P. Tobin
KCKasey L. Couts
Kasey L. Couts